The weekly litigation news digest is live. Subscribe now
Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases - EP3925607
The patent EP3925607 was granted to Vertex Pharmaceuticals Incorporated on Jul 16, 2025. The application was originally filed on Apr 14, 2015 under application number EP21175519A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3925607
- Application Number
- EP21175519A
- Filing Date
- Apr 14, 2015
- Status
- Granted And Under Opposition
- May 26, 2023
- Publication Date
- Jul 16, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
A pharmaceutical composition for treating cystic fibrosis comprising a combination of two spray-dried dispersions, each containing an amorphous form of a different active pharmaceutical ingredient (API), and a polymer. The first dispersion contains 70-90 wt% of the API (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and 10-30 wt% of a polymer, while the second dispersion contains 100 wt% of the API N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide. The composition is formulated as a tablet.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (45) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents